Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones [Yahoo! Finance]
GlucoTrack, Inc. (GCTK)
Company Research
Source: Yahoo! Finance
to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026 RUTHERFORD, N.J., March 27, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today provided a comprehensive recap of the critical operational milestones which have positioned the Company to submit an IDE to the U.S. Food and Drug Administration (FDA) for its novel continuous blood glucose monitoring (CBGM) technology, with a goal to file requisite documents with the FDA during Q2 of 2026. “In 2025 we made meaningful progress in advancing the development of our fully implantable continuous blood glucose monitoring technology and strengthening Glucotrack's foundation,” commented Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “The completion of our first-in-human study in Brazil and initiation
Show less
Read more
Impact Snapshot
Event Time:
GCTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GCTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GCTK alerts
High impacting GlucoTrack, Inc. news events
Weekly update
A roundup of the hottest topics
GCTK
News
- Glucotrack to File for FDA Exemption Based on 2025 Milestones [Yahoo! Finance]Yahoo! Finance
- Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 MilestonesGlobeNewswire
- Glucotrack to Present at LSI USA ’26 Medtech Innovation SummitGlobeNewswire
- Glucotrack Announces 3 New Patents to Monitor Blood Glucose [Yahoo! Finance]Yahoo! Finance
- Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM PlatformGlobeNewswire
GCTK
Sec Filings
- 3/27/26 - Form 8-K
- 3/13/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- GCTK's page on the SEC website